The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Varemoid     2-(3,4-dihydroxyphenyl)-5- hydroxy-7-(2...

Synonyms: Paroven, Relvene, Rutilemone, Monoxerutin, Monoxerutina, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of ZYMA SA

 

High impact information on ZYMA SA

  • This study evaluated the effects of HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) on the prevention and control of flight microangiopathy, and particularly on edema, in subjects with varicose veins flying for more than 7 hours [1].
 

Analytical, diagnostic and therapeutic context of ZYMA SA

  • Oxerutins in the form of Paroven 500 mg twice daily or identical placebo were given, and all patients were provided with elastic compression stockings [5].

References

  1. Flight microangiopathy in medium-to-long distance flights: prevention of edema and microcirculation alterations with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a prospective, randomized, controlled trial. Cesarone, M.R., Belcaro, G., Incandela, L., Geroulakos, G., Griffin, M., Lennox, A., DeSanctis, M.T., Acerbi, G. J. Cardiovasc. Pharmacol. Ther. (2002) [Pubmed]
  2. Treatment of diabetic microangiopathy and edema with HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides): a prospective, placebo-controlled, randomized study. Incandela, L., Cesarone, M.R., DeSanctis, M.T., Belcaro, G., Dugall, M., Acerbi, G. J. Cardiovasc. Pharmacol. Ther. (2002) [Pubmed]
  3. Paroven in the treatment of chronic venous insufficiency. Pulvertaft, T.B. The Practitioner. (1979) [Pubmed]
  4. HR (Venoruton1000, Paroven, 0-[beta-hydroxyethyl]-rutosides) vs. Daflon 500 in chronic venous disease and microangiopathy: an independent prospective, controlled, randomized trial. Belcaro, G., Cesarone, M.R., Bavera, P., Ricci, A., Renton, S., Leon, M., Ippolito, E., Dugall, M., Acerbi, G. J. Cardiovasc. Pharmacol. Ther. (2002) [Pubmed]
  5. Oxerutins in the prevention of recurrence in chronic venous ulceration: randomized controlled trial. Wright, D.D., Franks, P.J., Blair, S.D., Backhouse, C.M., Moffatt, C., McCollum, C.N. The British journal of surgery. (1991) [Pubmed]
 
WikiGenes - Universities